AI assistant
Lupin Ltd — Regulatory Filings 2026
Apr 10, 2026
61031_rns_2026-04-10_6d6d23cf-0a6a-4e73-8bed-44c4a62a7833.pdf
Regulatory Filings
Open in viewerOpens in your device viewer
==> picture [84 x 99] intentionally omitted <==
April 10, 2026
National Stock Exchange of India Limited BSE Limited Exchange Plaza, P. J. Towers, Dalal Street, Bandra Kurla Complex, Mumbai Samachar Marg, Bandra (East), Mumbai - 400 001 Mumbai - 400 051 Symbol: LUPIN Scrip Code: Equity - 500257
Subject: Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015
Dear Sir/Madam,
We are pleased to enclose a Press Release titled “Lupin Launches Dapagliflozin Tablets in the United States”.
The same is for your information and dissemination.
Thanking you,
For LUPIN LIMITED
Digitally signed by AMIT KUMAR GUPTA DN: c=IN, st=Maharashtra, 2.5.4.20=f72cf02f52d2a7e595b45b84659bdca28c8f26a939 AMIT KUMAR bb35835a169f2a237229a3, postalCode=400705, street=C701 Shivdarshan CHS Ltd Sector16 Plot No5 Navi Mumbai, GUPTA pseudonym=d3a468d0d03546efabffd2a7cb7aaaae, title=7875, serialNumber=de9bbd80d8994e4be9f0dd2399144eba7e782d70287df6aad1994f0b522fa08a, o=Personal, cn=AMIT KUMAR GUPTA Date: 2026.04.10 19:43:01 +05'30'
AMIT KUMAR GUPTA COMPANY SECRETARY & COMPLIANCE OFFICER (ACS -15754)
Encl.: a/a.
LUPIN LIMITED
Registered Office: 3[rd] Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel: (91-22) 6640 2323.
Corporate Identity Number: L24100MH1983PLC029442 [email protected] | www.lupin.com
Press Release
==> picture [68 x 70] intentionally omitted <==
BSE: 500257 NSE: LUPIN REUTERS: LUPIN.BO
BLOOMBERG: LPCIN
Lupin Launches Dapagliflozin Tablets in the United States
Mumbai, India, Naples, Fla, APRIL 10, 2026 : Global pharma major Lupin Limited (Lupin) today announced the launch of Dapagliflozin Tablets, 5 mg and 10 mg, in the United States following the approval for its Abbreviated New Drug Application from the U.S. FDA as bioequivalent to Farxiga® for the indications in the approved labeling.
About Lupin
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 24,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries - Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.
To know more, visit www.lupin.com or follow us on LinkedIn https://www.linkedin.com/company/lupin
For further information or queries, please contact
Rajalakshmi Azariah
Vice President & Global Head – Corporate Communications, Lupin [email protected]
Elise Titan
Director – U.S. Communications, Lupin [email protected]
*Safe Harbor Statement
Farxiga is a registered trademark of AstraZeneca AB.
1 | P a g e